Search Within

Hugo Castro-Malaspina

Formats
  1. Meeting Abstract (212)
  2. Journal Article (111)
  3. Conference Paper (8)
  4. Research Letter (2)
Groups
  1. Bone Marrow Transplant (333)
  2. Center for Hematologic Malignancies (333)
  3. Department of Medicine (333)
  4. Hematologic Malignancies, Division of (333)
  5. Sloan Kettering Institute Faculty (212)
  6. Pediatrics, Department of (210)

More Groups

People
  1. Esperanza Papadopoulos (211)
  2. Miguel-Angel Perales (187)
  3. Ann Jakubowski (185)
  4. Richard O'Reilly (184)
  5. Sergio Giralt (164)
  6. James Young (157)

More People

Years
  1. 2023 (1)
  2. 2022 (4)
  3. 2021 (4)
  4. 2020 (8)
  5. 2019 (13)
  6. 2018 (23)

More Years

Publications
  1. Blood (134)
  2. Biology of Blood and Marrow Transplantation (97)
  3. Bone Marrow Transplantation (34)
  4. Experimental Hematology (9)
  5. British Journal of Haematology (6)
  6. Journal of Clinical Oncology (5)

More Publications

Publishers
  1. American Society of Hematology (136)
  2. Elsevier Inc. (106)
  3. Nature Publishing Group (35)
  4. Elsevier Science, Inc. (11)
  5. John Wiley & Sons (8)
  6. American Society of Clinical Oncology (5)

More Publishers

Results (333)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The prognostic value of residual FDG-avidity prior to allogeneic stem cell transplantation for lymphoma
    Meeting Abstract

    Sauter, C. S.; Barker, J. N.; Zelenetz, A. D.; Fleming, S. E.; Castro-Malaspina, H.; Moskowitz, C. H.
    Blood (2009)

    Fulltext@MSK | Save
  • Absolute lymphocyte count at day 30 predicts survival in recipients of a T cell depleted allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Goldberg, J. D.; Lai, K. C.; Jakubowski, A. A.; Barker, J. N.; Boulad, F.; Castro-Malaspina, H. R.; Hsu, K. C.; Kernan, N.; O'Reilly, R. J.; Papadopoulos, E. B.; more...
    Biology of Blood and Marrow Transplantation (2009)

    Fulltext@MSK | Save
  • Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Perales, M. A.; Kewalramani, T.; Yahalom, J.; Castro-Malaspina, H.; Zhang, Z.; Vanak, J.; Zelenetz, A. D.; Moskowitz, C. H.
    British Journal of Haematology (2009)

    Fulltext@MSK | Save
  • Use of the tetanus toxoid, reduced dose diphtheria and pertussis vaccine (Tdap) in allogeneic transplant (alloHCT) recipients
    Meeting Abstract

    Papadopoulos, E. B.; Young, J. W.; Kernan, N. A.; Boulad, F.; Castro-Malaspina, H. R.; O'Reilly, R. J.; Prockop, S.; Scaradavou, A.; Taylor, J.; Ford, R.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Response to pneumococcal (PNCRM7) and Haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT)
    Journal Article

    Pao, M.; Papadopoulos, E. B.; Chou, J.; Heller, G.; Castro-Malaspina, H.; Jakubowski, A. A.; Kernan, N. A.; Perales, M. A.; Prokop, S.; Scaradavou, A.; more...
    Biology of Blood and Marrow Transplantation (2008)

    Fulltext@MSK | Save
  • Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Journal Article

    Castro-Malaspina, H.; Jakubowski, A. A.; Papadopoulos, E. B.; Boulad, F.; Young, J. W.; Kernan, N. A.; Perales, M. A.; Small, T. N.; Hsu, K.; Chiu, M.; more...
    Biology of Blood and Marrow Transplantation (2008)

    Fulltext@MSK | Save
  • Analysis of 121 allograft recipients for the treatment of lymphoma: Progressive disease by functional and/or CT imaging is a critical determinant of survival
    Meeting Abstract

    Sauter, C. S.; Moskowitz, C. H.; Barker, J. N.; Jakubowski, A. A.; Papadopoulos, E. B.; Perales, M. A.; Young, J. W.; Van Den Brink, M.; Zelenetz, A. D.; Castro-Malaspina, H. R.
    Blood (2007)

    Fulltext@MSK | Save
  • Phase II trial of a chemotherapy-only regimen of busulfan, melphalan, fludarabine and R-ATG followed by allogeneic T-cell depleted (TCD) hematopoietic stem cell transplants (HSCT) for the treatment of myeloid malignancies
    Meeting Abstract

    Boulad, F.; Jakubowski, A.; Papadopoulos, E.; Hsu, K. C.; Perales, M. A.; Van Den Brink, M.; Young, J. W.; Chiu, M.; Kernan, N. A.; Prockop, S. E.; more...
    Blood (2007)

    Fulltext@MSK | Save
  • Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies
    Journal Article

    Small, T. N.; Young, J. W.; Castro-Malaspina, H.; Prockop, S.; Wilton, A.; Heller, G.; Boulad, F.; Chiu, M.; Hsu, K.; Jakubowski, A.; more...
    Biology of Blood and Marrow Transplantation (2007)

    Fulltext@MSK | Save
  • Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease
    Journal Article

    Perales, M. A.; Ishill, N.; Lomazow, W. A.; Weinstock, D. M.; Papadopoulos, E. B.; Dastigir, H.; Chiu, M.; Boulad, F.; Castro-Malaspina, H. R.; Heller, G.; more...
    Bone Marrow Transplantation (2007)

    Fulltext@MSK | Save